

TNFA

Humanized anti-TNF alpha (Certolizumab Pegol) mAb

Catalog No.	CSB107A CSB107B	Quantity:	200 µg 1.0 mg
Alternate Names:	CDP870, PHA-738144, CIMZIA		
Description:	Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was devised to prevent complement fixation and antibody-mediated cytotoxicity as well as to markedly increase its half-life in the treatment of Crohn's disease and rheumatoid arthritis.		
Concentration:	1.0 mg/ml		
UniProt ID (target):	P01375		
Source:	CHO cell line		
Isotype:	Humanized Fab'-G1 kappa		
INN:	Certolizumab Pegol		
Specificity:	Human tumor necrosis factor inhibitor		
Biologic Activity:	Neutralizing		
Formulation:	PBS, pH 7.5		
Purity:	> 95% as determined by SDS-PAGE		
Reactivity:	Human		
Applications:	Functional studies, ELISA		
Storage & Stability:	Recommended storage, undiluted at 2-8°C for up to 1 week, or in working aliquots at -20°C to -80°C for up to 1 year. Avoid freeze/thaw cycles.		

NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.

